207 related articles for article (PubMed ID: 19781444)
1. Overexpression of the novel oncogene SALL4 and activation of the Wnt/beta-catenin pathway in myelodysplastic syndromes.
Shuai X; Zhou D; Shen T; Wu Y; Zhang J; Wang X; Li Q
Cancer Genet Cytogenet; 2009 Oct; 194(2):119-24. PubMed ID: 19781444
[TBL] [Abstract][Full Text] [Related]
2. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice.
Ma Y; Cui W; Yang J; Qu J; Di C; Amin HM; Lai R; Ritz J; Krause DS; Chai L
Blood; 2006 Oct; 108(8):2726-35. PubMed ID: 16763212
[TBL] [Abstract][Full Text] [Related]
3. [Expression of cell cycle control genes in myelodysplastic syndromes].
Shi J; Shao ZH; Liu H; Jia HR; Sun J; Bai J; Cao YR; Wang XL; Tu MF
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):10-4. PubMed ID: 15946501
[TBL] [Abstract][Full Text] [Related]
4. Expression dynamics of drug resistance genes, multidrug resistance 1 (MDR1) and lung resistance protein (LRP) during the evolution of overt leukemia in myelodysplastic syndromes.
Kurata M; Hasegawa M; Nakagawa Y; Abe S; Yamamoto K; Suzuki K; Kitagawa M
Exp Mol Pathol; 2006 Dec; 81(3):249-54. PubMed ID: 16566920
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional down-regulation of the Wnt antagonist SFRP1 in haematopoietic cells of patients with different risk types of MDS.
Reins J; Mossner M; Neumann M; Platzbecker U; Schumann C; Thiel E; Hofmann WK
Leuk Res; 2010 Dec; 34(12):1610-6. PubMed ID: 20471677
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of the bone marrow mononuclear cells from patients with myelodysplastic syndrome.
Qian J; Chen Z; Wang W; Cen J; Xue Y
Oncol Rep; 2005 Nov; 14(5):1189-97. PubMed ID: 16211284
[TBL] [Abstract][Full Text] [Related]
7. Activation of Wnt/beta-catenin/Tcf signaling pathway in human astrocytomas.
Sareddy GR; Panigrahi M; Challa S; Mahadevan A; Babu PP
Neurochem Int; 2009 Sep; 55(5):307-17. PubMed ID: 19576519
[TBL] [Abstract][Full Text] [Related]
8. Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes.
Wang F; Guo Y; Chen Q; Yang Z; Ning N; Zhang Y; Xu Y; Xu X; Tong C; Chai L; Cui W
J Hematol Oncol; 2013 Sep; 6(1):73. PubMed ID: 24283704
[TBL] [Abstract][Full Text] [Related]
9. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia.
Omidvar N; Kogan S; Beurlet S; le Pogam C; Janin A; West R; Noguera ME; Reboul M; Soulie A; Leboeuf C; Setterblad N; Felsher D; Lagasse E; Mohamedali A; Thomas NS; Fenaux P; Fontenay M; Pla M; Mufti GJ; Weissman I; Chomienne C; Padua RA
Cancer Res; 2007 Dec; 67(24):11657-67. PubMed ID: 18089795
[TBL] [Abstract][Full Text] [Related]
10. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
Maratheftis CI; Bolaraki PE; Voulgarelis M
Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analyses of beta-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): a possible role of Wnt pathway in GCTB tumorigenesis.
Matsubayashi S; Nakashima M; Kumagai K; Egashira M; Naruke Y; Kondo H; Hayashi T; Shindo H
Pathol Res Pract; 2009; 205(9):626-33. PubMed ID: 19324500
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the Doppel protein in acute myeloid leukaemias and myelodysplastic syndromes.
Travaglino E; Comincini S; Benatti C; Azzalin A; Nano R; Rosti V; Ferretti L; Invernizzi R
Br J Haematol; 2005 Mar; 128(6):877-84. PubMed ID: 15755294
[TBL] [Abstract][Full Text] [Related]
14. Accelerated cellular senescence in myelodysplastic syndrome.
Wang YY; Cen JN; He J; Shen HJ; Liu DD; Yao L; Qi XF; Chen ZX
Exp Hematol; 2009 Nov; 37(11):1310-7. PubMed ID: 19748549
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
Bernasconi P
Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941
[TBL] [Abstract][Full Text] [Related]
16. CD34+ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome.
Heinrichs S; Berman JN; Ortiz TM; Kornblau SM; Neuberg DS; Estey EH; Look AT
Br J Haematol; 2005 Jul; 130(1):83-6. PubMed ID: 15982348
[TBL] [Abstract][Full Text] [Related]
17. Myelodysplastic syndromes: molecular pathogenesis and genomic changes.
Nolte F; Hofmann WK
Ann Hematol; 2008 Oct; 87(10):777-95. PubMed ID: 18516602
[TBL] [Abstract][Full Text] [Related]
18. [The expression of beta-catenin and its significance in leukemia cells].
Mai YJ; Qiu LG; Li ZJ; Yu Z; Li CH; Wang YF; Wang GR; Li Q
Zhonghua Xue Ye Xue Za Zhi; 2007 Aug; 28(8):541-4. PubMed ID: 18078131
[TBL] [Abstract][Full Text] [Related]
19. Transcriptosome and serum cytokine profiling of an atypical case of myelodysplastic syndrome with progression to acute myelogenous leukemia.
Mahadevan D; DiMento J; Croce KD; Riley C; George B; Fuchs D; Mathews T; Wilson C; Lobell M
Am J Hematol; 2006 Oct; 81(10):779-86. PubMed ID: 16838325
[TBL] [Abstract][Full Text] [Related]
20. Identification of a stroma-mediated Wnt/beta-catenin signal promoting self-renewal of hematopoietic stem cells in the stem cell niche.
Kim JA; Kang YJ; Park G; Kim M; Park YO; Kim H; Leem SH; Chu IS; Lee JS; Jho EH; Oh IH
Stem Cells; 2009 Jun; 27(6):1318-29. PubMed ID: 19489023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
